Signia Announces Insio Charge&Go AX

The world’s first custom hearing aids with Contactless Charging, Bluetooth, & Streaming to Android and Apple iOS Devices

Expanding on its mission to enhance human performance, hearing aid innovator Signia today announced the general availability of its Insio Charge&Go AX custom hearing aids, the newest revolutionary device built upon Signia’s pioneering Augmented Xperience (AX) platform.

The first of its kind AX platform utilizes Signia’s ground-breaking Augmented Focus™ technology, which processes speech and background noise separately—using two dedicated processors—and combines them to deliver outstanding speech clarity in a fully immersive soundscape. Signia AX makes it possible for patients to focus on what they truly want to hear.

Signia Insio Charge&Go AX and Signia AX were recently named CES 2022 Innovation Awards Honorees in the Wearables and Accessibility categories, recognizing Signia’s success in optimizing listening through its iconic innovations.[1]

The Insio Charge&Go AX is the second family of Signia hearing aids built upon the AX platform, following the successful Spring 2021 launch of the Pure Charge&Go T AX RIC hearing aids. The Insio Charge&Go AX is the industry’s first family of custom-fitted in-the-canal (ITC) and in-the-ear (ITE) hearing aids to feature contactless charging, Bluetooth® connectivity, and the ability to stream from Android and Apple iOS devices. Because they are designed to fit comfortably in the patient’s ear, they also deliver the discretion that today’s hearing aid wearers demand.

“By taking the Augmented Xperience platform and adapting it for use in our newest custom hearing aids, Signia continues to combine world-class audiology and world’s first technologies to enhance human performance,” said Dr. Brian Taylor, Senior Director of Audiology for Signia. “The Insio Charge&Go AX hearing aids join the widely acclaimed, ground-breaking Pure Charge&Go T AX rechargeable RIC hearing aids in giving hearing care professional a wider range of solutions to fit patients’ needs, wants, and styles.”

Designed For All Patients’ Needs

Both the ITC and ITE Insio Charge&Go AX custom hearing aids are fully rechargeable and designed to support a broad range of patients’ needs. They come with a contactless charger for easy operation, meaning wearers don’t have to worry about charging positions when ensuring maximum battery life. And they connect seamlessly to iPhones and ASHA-compatible Android devices and feature convenient push-button control of smartphone functions.

All Insio Charge&Go AX custom hearing aids are designed for a high fitting rate. They are uniquely small and customized to the wearer’s ear canal for all-day comfort and higher patient satisfaction. They also come in a range of colors including Black, Dark Brown, Brown, Mocha, Tan, and Beige.

“As with all our hearing aids, we’re not just looking to help correct a loss,” stated Taylor. “Through iconic innovation and a consumer-centric approach, Signia also aims to give patients an edge. Our new custom, AX-based hearing aids are the first custom hearing aid with contactless charging that can be tailored to both the patient’s hearing loss and ear anatomy.”

According to studies, Signia AX results in greater than 25 percent better speech understanding in noise compared to users’ own hearing aids.[2] And 95 percent of study participants reported

exceptional speech understanding in their home environment.[3]

Backed by the Power of the Signia app

Like other Signia hearing aids, the new Insio Charge&Go AX hearing aids come with the award-winning Signia app, providing on-the-go support and intuitive access to hearing aid controls.

The Signia App provides wearers with streaming capabilities; tinnitus therapy; the AI-based Signia Assistant for a more personalized listening experience and 24/7 digital support; Signia Telecare for remote care support; and much more. It also allows wearers to activate Signia’s first-of-its-kind Face Mask Mode, which dramatically improves audibility for wearers communicating with someone in a face mask.


References

[1] The CES Innovation Awards are based upon descriptive materials submitted to the judges. CTA did not verify the accuracy of any submission or of any claims made and did not test the item to which the award was given.

[2] Signia White Paper. Based on transformation of the 1.8 dB SNR improvement using a value of the slope of the psychometric function (Wagener & Brand, 2005)

[3] Signia White Paper. 18/19 participants had a mean rating of speech intelligibility-related questions of more than 8.0 and 9.0, respectively

SourceSignia

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version